key: cord-0891907-whvss1xv
authors: Castanha, Priscila M S; Marques, Ernesto T A
title: Vaccine development during global epidemics: the Zika experience
date: 2020-05-06
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(20)30360-1
sha: 74e4c050d0b4cd15d94e72142e988b0f463c5744
doc_id: 891907
cord_uid: whvss1xv

nan

In The Lancet Infectious Diseases, Kathryn Stephenson and colleagues 5 report the final results of a phase 1 clinical trial on the safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules. The authors showed that their Zika vaccine formulation was well tolerated, immunogenic, and did not show signs of inducing any significant adverse medical outcome (eg, Guillain-Barré syndrome) through 52 weeks of follow-up. A two-dose prime-boost regimen of the vaccine, administered either via a standard schedule (weeks 0 and 4) or an accelerated schedule (weeks 0 and 2), elicited a robust Zika virus neutralising antibody response that peaked 2 weeks after the final vaccination, and then declined to a geometric mean titre of less than 100 by study week 16. The sharp decay in Zika virus neutralising antibody titres might be linked to poor induction of cellular immune responses by the inactivated vaccine. 6 This antigen formulation is still far from an ideal vaccine, and efforts to develop or refine promising Zika vaccine candidates must remain a priority. However, because of the progresses made we might be somewhat better prepared should a new Zika outbreak occur.

Despite low antibody durability after boost, it is possible that the level of immunological memory elicited by this vaccine formulation would allow for a quicker humoral immune response to a Zika infection, as has been shown for other flavivirus vaccines. 7, 8 This quick response might reduce levels of replicating virus enough to inhibit fetal infections. Nevertheless, safety issues still need to be addressed.

The small number of participants in Stephenson and colleagues' trial 5 does not allow the risk that this formulation can induce Guillain-Barré syndrome to be completely ruled out. Moreover, it is still uncertain whether low levels of anti-Zika antibody can affect the clinical outcome of dengue infection. Antidengue antibodies have been shown to enhance Zika virus infection in in-vitro, ex-vivo, and animal models, but the role of anti-Zika antibodies in dengue infections remains unclear. 9 In an ex-vivo human skin model, low titres of anti-Zika antibodies enhanced dengue infection of macrophages and dendritic cells, suggesting that a vaccine formulation that induces low immunogenicity might increase the risk for severe dengue. 10 This potential risk could probably be mitigated by administering Zika vaccine to individuals who have already been exposed to dengue.

We have learned a lot from efforts to develop a Zika vaccine, and the experience acquired during the Zika outbreak is reflected by the rapid response to the call for development of vaccines for coronavirus disease 2019. However, we should not forget or underestimate the challenges involved in vaccine development and that real solutions can occur only with consistent efforts and sustained investments. Our technological state allows a rapid head start, but vaccine development is not a sprint race, it is a marathon. Efforts to develop Zika vaccines must continue to be supported financially if we are to be prepared for future outbreaks.

We declare no competing interests.

CD4+ T cells promote humoral immunity and viral control during Zika virus infection

Five-year antibody persistence following a Japanese encephalitis chimeric virus vaccine (JE-CV) booster in JE-CV-primed children in the Philippines

Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51

The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis

Reciprocal immune enhancement of dengue and Zika virus infection in human skin